...
  • 主题
高级搜索  >
历史搜索 清空历史
首页> 外文期刊>Patient Preference and Adherence >A review of denosumab for the treatment of osteoporosis
【24h】

A review of denosumab for the treatment of osteoporosis

机译：对骨质疏松症治疗的Denosumab综述

获取原文
           
页面导航
  • 摘要
  • 著录项
  • 相似文献
  • 相关主题

摘要

Abstract: Osteoporosis is an age-related systemic skeletal disease characterized by low bone mass and microarchitectural deterioration of bone tissue, with a consequent increase in bone fragility. Bone remodeling involves two types of cells: osteoblasts and osteoclasts. Receptor activator of nuclear factor-κB ligand (RANKL) is a key regulator of the formation and function of bone-resorbing osteoclasts, and its cell surface receptor, receptor activator of nuclear factor-κB (RANK), is expressed by both osteoclast precursors and mature osteoclasts. Denosumab is a fully human monoclonal anti-RANKL antibody that inhibits the binding of RANKL to RANK, thereby decreasing osteoclastogenesis and bone-resorbing activity of mature osteoclasts. Although there are many medications available for the treatment of osteoporosis, inhibition of RANKL by denosumab has been shown to significantly affect bone metabolism. Denosumab appears to be a promising, highly effective, and safe parenteral therapy with good adherence for osteoporosis. Moreover, denosumab may be cost-effective therapy compared with existing alternatives. Therefore, in this review, we focus on studies of denosumab and the risks and benefits identified for this type of treatment for osteoporosis.
机译：摘要：骨质疏松症是一种与年龄相关的系统性骨骼疾病，其特征在于骨组织的低骨质量和微体系结构恶化，因此骨脆性增加。骨重塑涉及两种类型的细胞：成骨细胞和骨质体。核因子-κB配体（RANKL）的受体激活剂是骨再吸收骨质体的形成和功能的关键调节因子，其细胞表面受体，核因子-κB（等级）的受体活化剂是由骨骨骨蛋白前体表达的成熟的骨核糖籽。 Denosumab是一种完全的单克隆抗RANKL抗体，其抑制RANKL对等级的结合，从而降低了成熟骨细胞的骨细胞发生和骨吸收活性。虽然有许多可用于治疗骨质疏松症的药物，但已经显示出DeNosumab对Rankl的抑制显着影响骨代谢。 Denosumab似乎是具有良好依赖于骨质疏松症的有前途，高效和安全的肠胃外疗法。此外，与现有替代品相比，DeNosumab可能是具有成本效益的治疗。因此，在本次综述中，我们专注于对Denosumab的研究以及为骨质疏松症的这种治疗方法确定的风险和益处。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱：kefu@zhangqiaokeyan.com

京公网安备：11010802029741号 ICP备案号：京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有

  • 客服微信

  • 服务号